E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): A pediatric oncology group study

Blood

Volumn 91, Issue 3, 1998, Pages 1021-1028

  Hunger, Stephen P ^a   Fall, Majilinde Z ^a   Camitta, Bruce M ^a   Carroll, Andrew J ^a   Link, Michael P ^a   Lauer, Stephen J ^a   Mahoney, Donald H ^a   Pullen, D Jeanette ^a   Shuster, Jonathan J ^a   Steuber, C Philip ^a   Cleary, Michael L ^a  

^a c/o POG Operations Office ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER RECURRENCE; CHILD; CHILDHOOD CANCER; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 19; HUMAN; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DISEASE-FREE SURVIVAL; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; PROGNOSIS; RECURRENCE; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 18544407424     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Campana D, Pui C-H: Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance. Blood 85:1416, 1995
2. Hunger SP: Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: Clinical features and molecular pathogenesis. Blood 87:1211, 1996
3. Kamps MP, Murre CM, Sun X-H, Baltimore D: A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL. Cell 60:547, 1990
4. Nourse J, Mellentin JD, Galili N, Wilkinson J, Stanbridge E, Smith SD, Cleary ML: Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor. Cell 60:535, 1990
5. Hunger SP, Galili N, Carroll AJ, Crist WM, Link M, Cleary ML: The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias. Blood 77:687, 1991
6. Pui C-H, Raimondi SC, Hancock ML, Rivera GK, Ribeiro RC, Mahmoud HH, Sandlund JT, Crist WM, Behm FG: Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19)(q23; p13) or its derivative. J Clin Oncol 12:2601, 1994
7. Crist W, Boyett J, Jackson J, Vietti T, Borowitz M, Chauvenet A, Winick N, Ragab A, Mahoney D, Head D, Iyer R, Wagner H, Pullen J: Prognostic importance of the pre-B immunophenotype and other presenting features in B-lineage childhood acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 74:1252, 1989
8. Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, Vieti TJ, Look AT, Mahoney D, Ragab A, Pullen DJ, Land VJ: Poor prognosis of children with Pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13). A Pediatric Oncology Group Study. Blood 76:117, 1990
9. Raimondi SC, Behm FG, Roberson PK, Williams DL Pui C-H, Crist WM, Look AT, Rivera GK: Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). J Clin Oncol 8:1380, 1990
10. Mellentin JD, Nourse J, Hunger SP, Smith SD, Cleary ML: Molecular analysis of the t(1;19) breakpoint cluster region in pre-B cell ALL. Genes Chromosomes Cancer 2:239, 1990
11. Numata S, Kato K, Horibe K: New E2A/PBX1 fusion transcript in a patient with t(1;19)(q23;p13) acute lymphoblastic leukemia. Leukemia 7:1441, 1993
12. Izraeli S, Henn T, Strobl H, Ludwig WD, Kovar H, Haas OD, Harbott J, Bartram CR, Gardner H, Lion T: Expression of identical E2A-PBX1 fusion transcripts occurs in both pre-B and early pre-B immunological subtypes of childhood acute lymphoblastic leukemia. Leukemia 7:2054, 1993
13. Privitera E, Kamps MP, Hayashi Y, Inaba T, Shapiro LH, Raimondi SC, Behm F, Hendershot L, Carroll AJ, Baltimore D, Look AT: Different molecular consequences of the 1;19 chromosomal translocation in childhood B-cell precursor acute lymphoblastic leukemia. Blood 79:1781, 1992
14. Devaraj PE, Foroni L, Janossy G, Hoffbrand AV, Secker-Walker LM: Expression of the E2A-PBX1 fusion transcripts in t(1;19)(q23;p13) and der(19)t(1;19) at diagnosis and in remission of acute lymphoblastic leukemia with different B lineage immunophenotypes. Leukemia 9:821, 1995
15. Troussard X, Rimokh R, Valensi F, Leboeuf D, Fenneteau O, Guitard A-M, Manel A-M, Schillenger F, Leglise C, Brizard A, Gardais J, Lessard M, Flandrin G, MacIntyre E: Heterogeneity of t(1;19)(q23; p13) acute leukemias. Br J Haematol 89:516, 1995
16. Izraeli S, Janssen WSG, Haas OA, Harbott J, Brok-Simoni F, Walher JU, Kovar H, Henn T, Ludwig W-D, Reiter A, Rechavi G, Bartram CR, Gadner H, Lion T: Detection and clinical relevance of genetic abnormalities in pediatric acute lymphoblastic leukemia: A comparison between cytogenetic and polymerase chain reaction analyses. Leukemia 7:671, 1993
17. Privitera E, Rivolta A, Ronchetti D, Mosna G, Giudidi G, Biondi A: Reverse transcriptase/polymerase chain reaction follow-up and minimal residual disease detection in t(1;19)-positive acute lymphoblastic leukemia. Br J Haematol 92:653, 1996
18. Lanza C, Gottardi E, Gaidano G, Vivenza C, Parziale A, Perfetto F, Fornaci M, Barisone E, Madon G, Saglio G: Persistence of E2A/PBX1 transcripts in t(1;19) childhood acute lymphoblastic leukemia: Correlation with chemotherapy intensity and clinical outcome. Leuk Res 20:441, 1996
19. Kobayashi H, Maseki N, Homma C, Sakurai M, Kaneko Y: Clinical significance of chromosome abnormalities in childhood acute lymphoblastic leukemia in Japan. Leukemia 8:1954, 1994
20. Lampert F, Harbott J, Ritterbach J, Schellong G, Ritter J, Creutzig U, Riehm H, Rieter A: Karyotypes in acute childhood leukemias may lose prognostic significance with more intensive and specific chemotherapy. Cancer Genet Cytogenet 54:277, 1991
21. Camitta B, Mahoney D, Leventhal B, Lauer SJ, Shuster JJ, Adair S, Civin C, Munoz L, Steuber P, Strother D: Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 12:1383, 1994
22. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium-thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156, 1987
23. + acute lymphoblastic leukemia: Case report and review of the literature. Genes Chromosomes Cancer (in press)
24. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1, 1977
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
26. Lehmann EL: Nonparametrics: Statistical Methods Based on Ranks. San Francisco, CA, Holin-Day, 1975
27. Yamada M, Wasserman R, Lange B, Reichard BA, Womer RB, Rovera G: Minimal residual disease in childhood B-lineage lymphoblastic leukemia. N Engl J Med 323:448, 1990
28. Ito Y, Wasserman R, Galili N, Reichard BA, Shane S, Lange B, Rovera G: Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia. J Clin Oncol 11:546, 1993
29. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM: Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82:1929, 1993
30. Malinge MC, Mahon FX, Delfau MH, Daheron L, Kitzis A, Guilhot F, Tanzer J, Grandchamp B: Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under Interferon therapy. Br J Haematol 82:701, 1992
31. Thompson JD, Brodsky I, Yunis JJ: Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation. Blood 79:1629, 1992
32. Tobal K, Yin JAL: Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8;21). Blood 88:3704, 1996
33. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF: Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 226:317, 1997
34. Cox DR: Regression models and life-tables. JR Stat Soc B34:187, 1972
35. Radich J, Gehly G, Lee A, Avery R, Bryant E, Edmands S, Gooley T, Kassler P, Kirk J, Ladne P, Thomas ED, Appelbaum FR: Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 89:2602, 1997
36. van Rhee F, Marks DI, Lin F, Szydlo RM, Hochhaus A, Treleaven J, Delord C, Cross NCP, Goldman JM: Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: Comparison of blood and bone marrow. Leukemia 9:329, 1995
37. Lion T: Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia. Bone Marrow Transplant 14:505, 1994
38. Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, Edmands S, Kirk J, Lee A, Kessler P, Schoch G, Buckner CD, Sullivan KM, Appelbaum FR, Thomas ED: Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients. Blood 85:2632, 1995
39. Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G, Rambaldi A, Arcese W, Petti MC, Meloni G, Mendelli F, Grignani F, Masera G, Barbui T, Pilicci PG: Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet 340:1437, 1992
40. Huang W, Sun GL, Li XS, Cao Q, Lu Y, Jang GS, Zhang FQ, Chai JR, Wang ZY, Waxman S, Chen Z, Chen S-J: Acute promyelocytic leukemia: Clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/ polymerase chain reaction to predict relapse. Blood 82:1264, 1993
41. Miller WH Jr, Levine K, DeBlasio A, Frankel SR, Dmitrovsky E, Warrell RP Jr: Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood 82:1689, 1993
42. Laczika K, Mitterbauer G, Korninger L, Knobl P, Schwarzinger I, Kapiotis S, Haas OA, Kyrle PA, Pont J, Oehler L, Purtscher B, Thalhammer F, Lechner K, Jaeger U: Rapid achievement of PML-RAR alpha polymerase chain reaction (PCR)-negativity by combined treatment with all-trans-retinoic acid and chemotherapy in acute promyelocytic leukemia: A pilot study. Leukemia 8:1, 1994
43. Diverio D, Pandolfi PP, Biondi A, Avvisati G, Petti MC, Mandelli F, Pelicci G, Lo Coco F: Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. Blood 82:3556, 1993
44. Fukitani H, Naoe T, Yoshida H, Kiyoi H, Miyawaki S, Morishita H, Sano F, Kamibayashi H, Matsue K, Miyake T, Hasegawa S, Ueda Y, Kato Y, Kabayashi H, Shimazaki M, Kurane R, Sakota H, Masaki K, Wakayama T, Tohyama K, Nonaka Y, Natori and the Leukemia Study Group of the Ministry of Health and Welfare (Kouseisho): Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia. Leukemia 9: 588, 1995
45. Chang KS, Fan YH, Stass SA, Estey EH, Wang G, Trujillo JM, Erickson P, Drabkin H: Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia. Oncogene 8:983, 1993
46. Nucifora G, Larson RA, Rowley JD: Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 82:712, 1993
47. Maruyama F, Stass SA, Estey EH, Cork A, Hirano M, Ino T, Freireich, EJ, Yang P, Chang KS: Detection of AML1/ETO fusion transcript as a tool for diagnosing t(8;21) positive acute myelogenous leukemia. Leukemia 8:40, 1994
48. Kusec R, Laczika K, Knobl P, Friedl J, Greinix H, Kahls P, Linkesch W, Schwarzinger I, Mitterbauer G, Purtscher B, Haas OA, Lechner K, Jaeger U: AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 8:735, 1994